Illia Petrov

Associate Director, AI & Data Science in Clinical Trials      

Business development professional with over 10 years experience in Biotech R&D departments and CROs. Proven ability in identifying partnering opportunities among academics, startups, pharma, and investors. Proficient in developing business strategies for early-stage technology development and performing due diligence for scientific and commercial evaluation.

Author in
AI & Digital   Startups & Deals   Clinical Trials   Biotech   Tools & Methods   Novel Therapeutics  


Recent articles from Illia

The Promise of Chatbots in Clinical Trials

   1097
The Promise of Chatbots in Clinical Trials

In the rapidly changing field of clinical trials, chatbots are becoming valuable tools for data analysis. These AI-driven conversational agents streamline data collection, boost patient engagement, and enhance the accuracy of data management. By automating interactions with patients, chatbots ensure consistent and precise data collection, reducing human error and operational costs. They also provide real-time insights, allowing researchers to monitor trial progress and make timely adjustments.

Despite these benefits, challenges such as biases in AI algorithms, lack of standardization, and usability issues persist. The accuracy of chatbots is influenced by the quality of data and the sophistication of machine learning algorithms. Nevertheless, their potential to transform clinical trial data analysis is considerable, offering scalable, cost-effective solutions that improve patient experience and data reliability. Future advancements in AI and machine learning, along with rigorous validation and standardization, will be crucial for the successful integration of chatbots into clinical trial processes.

This blog post explores the advantages, challenges, and future prospects of using chatbots in clinical trial data analysis, providing a thorough overview of their current and potential impact on the field.

How Modern Biotechnology is Shaping Our Future

   1950
How Modern Biotechnology is Shaping Our Future

Covid 19 pandemic that we went through revealed the fragility of our world. Despite the undeniable technological advancements of the past century, the challenges we are facing are still numerous and require immediate action. The midway report on Sustainable Development Goals released by the UN in 2023 showed that out of ca. 140 measurable targets, 50% show moderate or severe deviations from the desired trajectory and more than 30% have experienced no progress or regression below the 2015 baseline.

Xcell Biosciences and ElevateBio Forge Partnership to Enhance Cell and Gene Therapy Development

   1212
Xcell Biosciences and ElevateBio Forge Partnership to Enhance Cell and Gene Therapy Development

Xcell Biosciences, Inc., a notable company in the field of cell and gene therapy applications, has recently unveiled a strategic partnership with ElevateBio, LLC. This collaboration is set to explore innovative methods to augment the therapeutic efficacy of cell and gene therapies. A key highlight of this alliance is ElevateBio's induction as the inaugural participant in Xcellbio’s AVATAR Foundry™ beta program. Moreover, the partnership is strengthened by the appointment of Michael Paglia, Chief Technology Officer at ElevateBio’s BaseCamp®, to Xcellbio’s Scientific Advisory Board.

C4X Discovery: Advancing Drug Discovery with NRF2 Activator Program

   1039

C4X Discovery Holdings plc (AIM: C4XD), a drug discovery company, recently announced a significant milestone in its partnership with AstraZeneca. The company received an $11 million payment, a testament to the preclinical advancements in its NRF2 Activator program, reflecting a promising start to 2024 for C4XD.

C4 Therapeutics and Merck Collaborate on Innovative Cancer Treatment

   780
C4 Therapeutics and Merck Collaborate on Innovative Cancer Treatment

In a recent move in the biotechnology sector, C4 Therapeutics, Inc. (C4T) has announced a collaboration with pharmaceutical giant Merck (MRK). This partnership is centered on the development of degrader-antibody conjugates (DACs), focusing on a key oncology target.

Vandria Gains Momentum with $20.6M Funding to Propel Novel CNS and Mitochondrial Therapies

   986
Vandria Gains Momentum with $20.6M Funding to Propel Novel CNS and Mitochondrial Therapies

Vandria SA, a Swiss biotechnology firm specializing in mitochondrial therapeutics, recently announced a significant milestone in its journey. The company has secured $20.6 million (CHF18 million) in Series A financing, led by ND Capital, supplemented by high net worth private investors. This funding is a testament to Vandria's emergence from its initial stealth phase and marks its readiness to advance into the clinical stage.